World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
126
Citations
93153
World Ranking
2873
National Ranking
1598

Andrew X. Zhu publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Andrew X. Zhu sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 621 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Andrew X. Zhu D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Andrew X. Zhu sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 126 D-Index — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Andrew X. Zhu is affiliated with Harvard University in the United States and has made substantial contributions to the field of medicine, specializing primarily in oncology and hepatology. Their research focuses on liver-related cancers and diseases, encompassing hepatocellular carcinoma, cholangiocarcinoma, and broader hepatic oncology studies.

The scientist's work spans several key topics, including:

  • Hepatocellular Carcinoma Treatment and Prognosis
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Pancreatic and Hepatic Oncology Research
  • Colorectal Cancer Treatments and Studies
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Liver Disease Diagnosis and Treatment

Andrew X. Zhu has contributed to numerous peer-reviewed publications, with frequent appearances in prominent journals such as the Journal of Clinical Oncology, Annals of Oncology, Journal of Hepatology, Clinical Cancer Research, and Liver Cancer. Their scholarly output reflects a strong presence in these high-impact venues.

Frequent collaborators in research include:

  • Richard S. Finn
  • Masatoshi Kudo
  • Peter R. Galle
  • Ann-Lii Cheng
  • Lipika Goyal

Selected recent papers exemplify the scope and focus of Andrew X. Zhu's work:

  • Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma (2020), published in New England Journal of Medicine
  • Immunotherapies for hepatocellular carcinoma (2021), published in Nature Reviews Clinical Oncology
  • Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma (2021), published in Journal of Hepatology
  • Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma (2020), published in Journal of Clinical Oncology
  • Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study (2020), published in The Lancet Oncology

The publication record and areas of study indicate a concentrated expertise in tumor biology, immunotherapy approaches for liver cancers, and clinical trial research design.

Andrew X. Zhu's main fields of study are medicine, with a significant subfield focus on oncology, hepatology, surgery, epidemiology, and cancer research. The interdisciplinary nature of their work is reflected in the integration of clinical oncology with molecular and diagnostic research.

Best Publications

  • Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

    Richard S Finn;Shukui Qin;Masafumi Ikeda;Peter R Galle

  • Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

    Jorge A. Marrero;Laura M. Kulik;Claude B. Sirlin;Andrew X. Zhu

  • AASLD guidelines for the treatment of hepatocellular carcinoma

    Julie K. Heimbach;Laura M. Kulik;Richard S. Finn;Claude B. Sirlin

  • Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

    Christopher G Willett;Yves Boucher;Emmanuelle di Tomaso;Dan G Duda

  • EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer

    Josep M. Llovet;Michel Ducreux;Riccardo Lencioni;Adrian M. Di Bisceglie

  • NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

    Al B Benson;Thomas A. Abrams;Edgar Ben-Josef;P. Mark Bloomston

  • Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

    Andrew X Zhu;Richard S Finn;Julien Edeline;Stephane Cattan

  • Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

    Josep M. Llovet;Adrian M. Di Bisceglie;Jordi Bruix;Barnett S. Kramer

  • Immunotherapies for hepatocellular carcinoma.

    Josep M Llovet;Josep M Llovet;Josep M Llovet;Florian Castet;Mathias Heikenwalder;Mala K Maini

  • Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Andrew X Zhu;Yoon-Koo Kang;Chia-Jui Yen;Richard S Finn

  • Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

    Richard S. Finn;Baek-Yeol Ryoo;Philippe Merle;Masatoshi Kudo

  • Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

    Richard S. Finn;Masafumi Ikeda;Andrew X. Zhu;Max W. Sung

  • Ramucirumab Versus Placebo as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH): A Randomised, Double-Blind, Multicentre, Phase 3 Trial

    Andrew X. Zhu;Joon Oh Park;Baek Yeol Ryoo;Chia Jui Yen

  • Differentiating the pathologies of cerebral malaria by postmortem parasite counts.

    Terrie E Taylor;Wenjiang J Fu;Wenjiang J Fu;Richard A Carr;Richard O Whitten

  • Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

    Cristina R. Ferrone;Giovanni Marchegiani;Theodore S. Hong;David P. Ryan

  • The role of signaling pathways in the development and treatment of hepatocellular carcinoma.

    S Whittaker;R Marais;A X Zhu

  • Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

    Ghassan K. Abou-Alfa;Ghassan K. Abou-Alfa;Teresa Macarulla;Milind M. Javle;Robin K. Kelley

  • Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping

    Darrell R. Borger;Kenneth K. Tanabe;Kenneth C. Fan;Hector U. Lopez

  • Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise

    Supriya K. Saha;Andrew X. Zhu;Charles S. Fuchs;Gabriel A. Brooks

  • Intrahepatic Cholangiocarcinoma: An International Multi-Institutional Analysis of Prognostic Factors and Lymph Node Assessment

    Mechteld C. De Jong;Hari Nathan;Georgios C. Sotiropoulos;Andreas Paul

Frequent Co-Authors

David P. Ryan
David P. Ryan Harvard University
Jeffrey W. Clark
Jeffrey W. Clark Harvard University
Masatoshi Kudo
Masatoshi Kudo Kindai University
Richard S. Finn
Richard S. Finn University of California, Los Angeles
Cristina R. Ferrone
Cristina R. Ferrone Harvard University
Josep M. Llovet
Josep M. Llovet University of Barcelona
Dan G. Duda
Dan G. Duda Harvard University
Rakesh K. Jain
Rakesh K. Jain Harvard University
Dushyant V. Sahani
Dushyant V. Sahani University of Washington
Jeffrey A. Meyerhardt
Jeffrey A. Meyerhardt Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens the door to a variety of online degree options beyond traditional MD programs. Many students choose healthcare administration as a flexible alternative. Accredited programs like the cahme master’s are highly regarded for those interested in leadership and management roles within healthcare.

For working nurses looking to advance, there are opportunities to earn a rn to bsn online with no clinicals degree. These online courses can be completed without in-person clinicals, making them more convenient for those balancing work or family responsibilities.

Advanced practice nurses can fast-track their education with the quickest dnp program options now available. These programs can often be finished in less time compared to traditional routes.

For those concerned about research requirements, there are now dnp programs without dissertation that streamline the process and focus on applied practice. Overall, the rise of online healthcare degrees opens new pathways and offers flexibility for a wide range of students.

Best Scientists Citing Andrew X. Zhu

Trending Scientists

Recently Published Articles